Renal Cell Carcinoma Research Reagents

Renal cell carcinoma (RCC) accounts for approximately 90% of kidney cancers, with clear cell RCC (ccRCC) as the predominant subtype. VHL gene inactivation leads to HIF-α stabilization and constitutive VEGF-driven angiogenesis. First-line treatment now combines immune checkpoint inhibitors with anti-angiogenic TKIs, while belzutifan (HIF-2α inhibitor) represents the first therapy directly targeting the VHL-HIF axis.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

Renal Cell Carcinoma Research Reagents - key pathogenic pathways and research targets

Fig. 1 Key pathogenic pathways and research targets in renal cell carcinoma. VHL-HIF-VEGF axis, CA-IX expression, and PD-1/PD-L1 immune checkpoint. abinScience product targets highlighted in orange.

abinScience provides validated antibodies, recombinant proteins, and ELISA kits for key renal cell carcinoma research targets. All products are manufactured by our parent company AtaGenix Laboratories under ISO quality systems. Browse products below or contact us for custom antibody development.

Key Research Targets

VEGF / VEGFR2 — VEGF overexpression driven by VHL loss is the hallmark of ccRCC. Anti-VEGF antibodies and recombinant VEGFR2 proteins support angiogenesis research, TKI mechanism studies, and VEGF-based biomarker development for anti-angiogenic therapy response prediction.
→ Browse VEGF/VEGFR antibodies & proteins

HIF-2α (EPAS1) — HIF-2α is the primary transcription factor stabilized upon VHL loss in ccRCC, directly driving VEGF, PDGF, and cyclin D1 expression. Anti-HIF-2α antibodies enable nuclear accumulation detection by IHC and belzutifan mechanism-of-action research.
→ Browse HIF-2α antibodies & proteins

CA-IX (Carbonic Anhydrase IX) — CA-IX is a HIF-1α target gene product strongly expressed on ccRCC cells but absent from most normal tissues. Anti-CA-IX antibodies support IHC-based subtype confirmation, CA-IX-targeted radioimmunotherapy research, and serum CA-IX prognostic biomarker measurement.
→ Browse CA-IX antibodies & proteins

PD-L1 (CD274) — PD-L1 expression in RCC informs risk stratification and treatment selection. Anti-PD-L1 antibodies support tumor microenvironment profiling, TIL exhaustion studies, and combination immunotherapy optimization research.
→ Browse PD-L1 antibodies & proteins

References

1. Motzer RJ, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277-1290. DOI

2. Choueiri TK, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829-841. DOI

3. Choueiri TK, et al. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan. Lancet Oncol. 2021;22(4):519-529. DOI

4. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499(7456):43-49. DOI

5. Rini BI, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116-1127. DOI